PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
Martina S.J. McDermott(University of California, Los Angeles), Norma O’Donovan(Dublin City University)
Cited by 42
Related Papers
Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
|Clinical Cancer Research|2023|48
Predictive biomarkers for dasatinib treatment in melanoma
|Oncoscience|2014|8